HEPA - Hepion Pharmaceuticals, Inc.
IEX Last Trade
0.471
-0.020 -4.246%
Share volume: 0
Last Updated: Fri 27 Dec 2024 06:19:16 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.49
-0.02
-4.07%
Fundamental analysis
10%
Profitability
0%
Dept financing
10%
Liquidity
50%
Performance
10%
Performance
5 Days
-0.98%
1 Month
-22.78%
3 Months
-27.21%
6 Months
-55.00%
1 Year
-86.21%
2 Year
-91.32%
Key data
Stock price
$0.47
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.50 - $3.49
52 WEEK CHANGE
-$84.72
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Robert T. Foster
Region: US
Website: hepionpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: hepionpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Hepion Pharmaceuticals, Inc. focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.
Recent news